Coyne, Daniel W. http://orcid.org/0000-0001-9786-5235
Sprague, Stuart M.
Vervloet, Marc
Ramos, Rosa
Kalantar-Zadeh, Kamyar
Funding for this research was provided by:
vifor pharma
Article History
Received: 3 August 2021
Accepted: 26 December 2021
First Online: 9 February 2022
Declarations
:
: Dr Coyne is a consultant and formerly a speaker for Fresenius Medical Care Renal Therapies Group and a consultant for Ardelyx, AstraZeneca, FibroGen, GlaxoSmithKline, Otsuka, and Vifor Pharma. Dr Sprague receives consultancy fees from OPKO Health, Vifor Pharma, Amgen, Ardelyx, and Fresenius Medical Care Renal Therapies Group and research funding from Abbott, Amgen, Ardelyx, OPKO Health, Reata Pharmaceuticals, and Vifor Pharma. Dr Vervloet has received fee or research support from ERA-EDTA, Dutch Kidney Foundation, Health Holland, Vifor Fresenius Medical Care Renal Pharma, Fresenius Medical Care, Medice, Amgen, Otsuka, Kyowa Kirin, Cablon Medical, Medice, and Shire. Dr Ramos is an employee of Fresenius Medical Care. Dr Kalantar-Zadeh has received honoraria and/or support from Abbott, AbbVie, Alexion, American Society of Nephrology, Amgen, AstraZeneca, AVEO, Chugai, DaVita, Fresenius, Fresenius Kabi, Genentech, Haymarket Media, Hofstra Medical School, Hospira, International Federation of Kidney Foundations, International Society for Hemodialysis, International Society of Renal Nutrition and Metabolism, Japanese Society for Dialysis Therapy, Keryx, National Institutes of Health, National Kidney Foundation, Novartis, OPKO, Pfizer, Relypsa, Resverlogix, Sandoz, Sanofi, Shire, UpToDate, Vifor, and ZS Pharma.
: Not applicable.
: Not applicable.
: Not applicable.